贝伐单抗
胶质母细胞瘤
血管生成素2
医学
生物标志物
肿瘤科
内科学
血管内皮生长因子受体
血管生成素受体
化疗
血管内皮生长因子
癌症研究
化学
生物化学
作者
Marianne Labussière,Caroline Cheneau,Claudia Prahst,Jaime Gállego Pérez‐Larraya,Patrizia Farina,Giuseppe Lombardi,Karima Mokhtari,Amithys Rahimian,Jean-Yves Delattre,Anne Eichmann,Marc Sanson
标识
DOI:10.3109/07357907.2015.1088948
摘要
Despite encouraging response rate of bevacizumab (BVZ) in recurrent glioblastoma, many patients do not respond to this schedule and most of the responders develop an early relapse. Plasma concentrations of VEGF, PlGF, Ang2, and sTie2 were assessed by ELISA before and during BVZ treatment in seventy patients. Baseline levels of VEGF-A, and PlGF were higher in patients than in healthy volunteers, whereas no difference was found for Ang2, and sTie2. No biomarker at baseline was associated with response, PFS or OS. At recurrence, the authors observed an increase of Ang2 suggesting that Ang2/sTie2 could be involved in the resistance to BVZ.
科研通智能强力驱动
Strongly Powered by AbleSci AI